Magnesium
What it is
Magnesium is an essential mineral involved in over 300 enzymatic reactions in the body, including energy production, protein synthesis, DNA repair, muscle contraction, and nerve signalling. It is the fourth most abundant mineral in the human body.
Dietary sources include leafy green vegetables, nuts, seeds, legumes, wholegrains, and dark chocolate. Despite this range of sources, inadequate magnesium intake is common in Western populations. Surveys consistently find that large proportions of adults in the UK and US do not meet recommended daily intakes, largely due to food processing, reduced soil mineral content, and dietary patterns low in whole plant foods. This should be distinguished from clinical deficiency, which is less prevalent and requires biochemical confirmation. Inadequate intake creates a risk of insufficiency over time; it does not automatically mean a person is currently deficient.
Magnesium is available in multiple supplemental forms with meaningfully different properties. This entry addresses each relevant form separately, because the evidence generated using one form does not automatically transfer to another.
What the evidence shows
Deficiency correction is where the evidence is clearest and most consistent. In individuals with confirmed deficiency or insufficiency, magnesium supplementation reliably restores serum and intracellular magnesium levels and is often associated with improvement in symptoms such as fatigue, muscle cramps, and poor sleep, though these symptoms are multifactorial and not specific to magnesium deficiency alone. The evidence for this outcome is consistent across multiple forms, though bioavailability differences between forms affect the dose required.
Sleep quality has a moderate evidence base, with an important population caveat. Several RCTs in older adults and individuals with low magnesium status show improvements in sleep onset, sleep duration, and subjective sleep quality. The evidence is less consistent in younger, generally healthy adults with adequate magnesium status, where two small RCTs found no significant benefit on objective sleep measures. The widely promoted claim that magnesium improves sleep in the general population extends beyond what the current evidence supports.
Muscle cramps and exercise recovery show moderate evidence, again concentrated in individuals with low or borderline magnesium status. Several RCTs show reductions in muscle cramps and improved recovery in athletes and older adults with dietary magnesium insufficiency. A Cochrane review found weaker evidence for nocturnal leg cramps in the general older adult population without confirmed deficiency.
Blood pressure has a moderate evidence base in hypertensive adults. A meta-analysis of 34 RCTs found modest but consistent reductions in systolic and diastolic blood pressure with magnesium supplementation, which may be clinically relevant at a population level, with effects more pronounced in individuals with lower baseline magnesium status.
Anxiety and perceived stress show early-stage evidence. Several small RCTs have found modest reductions in self-reported anxiety and stress, particularly in individuals with low magnesium status. Effect sizes are small, studies are short, and the evidence base is insufficient to support confident claims in the general population.
Sleep quality in replete healthy adults has insufficient evidence. The available RCT data in individuals with normal magnesium status has not demonstrated significant benefit on objective sleep measures.
What the evidence does not show
The widespread commercial claim that magnesium supplementation improves sleep, reduces anxiety, and boosts energy in the general population is not well-supported by the evidence. The benefits seen in trials are predominantly concentrated in individuals with low or deficient baseline status. Supplementing when already replete produces smaller and less consistent effects.
There is no strong evidence that magnesium supplementation meaningfully improves cognitive performance, reduces depression, or prevents cardiovascular disease in generally healthy adults with normal status.
The assumption that all magnesium supplements produce equivalent effects regardless of form is not supported. Bioavailability differences between forms are real, though their precise magnitude and translation to clinical outcomes varies across studies and measurement methods.
Form and dose considerations
Magnesium form selection is one of the most clinically relevant decisions in supplementation, and one of the most commercially confused. The differences between forms are real and meaningful, though the evidence for form-specific clinical outcomes is more limited than is sometimes implied.
Magnesium oxide has consistently lower bioavailability than organic salts and chelated forms across multiple studies, though the precise absorption difference varies by study design and measurement method. It is the most common and cheapest supplemental form. An important nuance: several positive trials for magnesium outcomes, including the most cited sleep RCT, used magnesium oxide. This suggests that sufficiently high doses of oxide may partially overcome its absorption disadvantage for some outcomes, though organic forms remain preferable where equivalent doses are tolerated.
Magnesium citrate has higher bioavailability than oxide and a reasonable evidence base for general deficiency correction and muscle function. It has a mild laxative effect at higher doses, which can be dose-limiting but is occasionally used therapeutically.
Magnesium bisglycinate and glycinate are chelated forms with higher bioavailability and good gastrointestinal tolerability. Several trials showing sleep and anxiety benefits used chelated or organic forms, though direct head-to-head comparisons between forms for these outcomes are limited. It is not yet possible to conclude definitively that chelated forms are superior to other well-absorbed forms for sleep or anxiety specifically.
Magnesium malate combines magnesium with malic acid, a Krebs cycle intermediate. There is a plausible mechanistic rationale for muscle and energy outcomes, and some trial evidence, but the form-specific evidence base is more limited than for citrate or bisglycinate.
Magnesium taurate combines magnesium with taurine. Some evidence for cardiovascular and blood pressure outcomes exists, but separating the contribution of magnesium from that of taurine is difficult in available trials.
The upper tolerable intake from supplements is 350mg elemental magnesium per day for most adults. Labelled doses often refer to the total compound weight rather than elemental magnesium content, which varies by form and should be checked on the product label.
Who the evidence applies to
The deficiency correction, sleep, and muscle cramp evidence applies most clearly to individuals with confirmed low or borderline magnesium status, older adults, athletes with high training loads, individuals with type 2 diabetes, and those taking medications that deplete magnesium including proton pump inhibitors, diuretics, and some antibiotics.
The blood pressure evidence applies most consistently to hypertensive adults with low dietary magnesium intake.
Younger, generally healthy adults with adequate dietary magnesium intake and normal serum status represent the population least likely to benefit from supplementation across most outcomes.
Safety and contraindications
Magnesium is well tolerated at standard doses. The main side effect is gastrointestinal: high doses, particularly of oxide and citrate forms, can cause diarrhoea and abdominal discomfort. This is dose-dependent and form-dependent, with bisglycinate and malate generally better tolerated.
Individuals with chronic kidney disease should seek medical advice before supplementing, as impaired renal function reduces the ability to excrete excess magnesium.
Magnesium can reduce the absorption of certain antibiotics including tetracyclines and fluoroquinolones through chelation. It can also interact with bisphosphonates and some diuretics. Anyone taking regular medication should check with their prescriber or pharmacist before supplementing.
What can reasonably be concluded
Inadequate magnesium intake is common in Western populations and is worth addressing through diet or supplementation in individuals at risk. Biochemical testing provides the most direct evidence of status. Serum magnesium is the most accessible measure and is useful for identifying frank deficiency, though it reflects only a small fraction of total body magnesium and can be normal even when intracellular stores are suboptimal. Red blood cell magnesium is sometimes used as a more sensitive marker of intracellular status, though its clinical utility is not fully standardised across laboratories.
For individuals with confirmed deficiency or insufficiency, supplementation is well-evidenced. Form selection matters: organic salts and chelated forms have consistently better bioavailability than oxide, and citrate or bisglycinate are reasonable first choices depending on tolerability and cost. Where specific outcomes such as sleep or anxiety are the primary concern, chelated forms have been used in more of the positive trials, though this may reflect study design and formulation trends rather than confirmed superiority in head-to-head comparisons. Direct comparative evidence between forms for clinical outcomes remains limited.
For generally healthy adults with adequate dietary intake and normal status, the case for routine supplementation is less well-supported than commercial messaging suggests. Form matters for absorption and tolerability; its impact on specific clinical outcomes is less well established than is sometimes implied. Where evidence is limited or inconsistent, conclusions should be treated as provisional and subject to revision as further trials are published.